COMPOUND BASED ON ORYDALMINE STRUCTURE AND USE THEREOF

WIPO Patent Application WO/2024/083146

A1

The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the central nervous system such as pain, drug addiction and depression. The present invention also relates to the preparation and the use of the compound.

LI WENMING (CN)
LI XIAOBO (CN)
GUO GUANGZHU (CN)
PEI XIAOLIN (CN)
ZHANG YU (CN)
WANG JINGYING (CN)
LI XINCHUN (CN)
YU XIAOLEI (CN)
PENG LIJIAO (CN)
ZHOU LIYING (CN)
GAN LELING (CN)
LI ERYAO (CN)
YU GUOKUN (CN)
LIU YANAN (CN)

PCT/CN2023/125192

April 25, 2024

October 18, 2023

Click for automatic bibliography generation  

BEIJING TIDE PHARMACEUTICAL CO LTD (CN)

C07D455/03; A61K31/4375; A61P25/00; C07D498/14

CN109384780A	2019-02-26
CN1900076A	2007-01-24
CN101037436A	2007-09-19
KR20120032660A	2012-04-06
US3420834A	1969-01-07

ZHANG, HONGWEI ET AL.: "Development of a Highly Sensitive and Specific ELISA Method for the Determination of l-corydalmine in SD Rats with Monoclonal Antibody", JOURNAL OF CHROMATOGRAPHY B, vol. 1073, 14 September 2017 (2017-09-14), pages 163 - 169, XP085335978, DOI: 10.1016/j.jchromb.2017.09.022
T. KAMETANI ET AL.: "A Total Synthesis of Kikemanine", JOURNAL OF THE CHEMICAL SOCIETY, vol. 20, 1 January 1971 (1971-01-01), pages 3318 - 3321, XP008123736

LIU , SHEN & ASSOCIATES (CN)

View/Download PDF      PDF Help

Previous Patent: ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION

Next Patent: COMMUNICATION SYSTEM